Cargando…

Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial

Detalles Bibliográficos
Autores principales: Schmidinger, M., Shariat, S.F., Fajkovic, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808104/
https://www.ncbi.nlm.nih.gov/pubmed/33421736
http://dx.doi.org/10.1016/j.esmoop.2020.100035